Zhejiang Doer Biologics Co., Ltd.
Clinical trials sponsored by Zhejiang Doer Biologics Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to shrink hard-to-treat gut tumors Results expected Apr 2027 (estimated)
- New hope for advanced cancer: experimental drug DR30206 enters human testing Results expected Jul 2027 (estimated)
-
New drug combo aims to shrink hard-to-treat gut tumors
Disease control Recruiting nowThis study tests a new drug called DR30206 combined with standard treatments for people with advanced or spreading gastrointestinal cancers, like colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. About 186 adults in China will take part.
Phase 1/2 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug DR30206 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called DR30206 in about 216 adults with advanced or metastatic solid tumors who have no other treatment options. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive t…
Phase 1 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC